Nisa Investment Advisors’s Lexicon Pharmaceuticals LXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $6.22K | Hold |
2,592
| – | – | ﹤0.01% | 2580 |
|
|
2026
Q1 | $4.04K | Hold |
2,592
| – | – | ﹤0.01% | 2500 |
|
|
2025
Q4 | $2.98K | Hold |
2,592
| – | – | ﹤0.01% | 2544 |
|
|
2025
Q3 | $3.5K | Hold |
2,592
| – | – | ﹤0.01% | 2514 |
|
|
2025
Q2 | $2.45K | Buy |
2,592
+1,992
| +332% | +$1.29K | ﹤0.01% | 2564 |
|
|
2025
Q1 | $276 | Buy |
+600
| New | +$379 | ﹤0.01% | 2883 |
|
|
2024
Q4 | – | Sell |
-147
| Closed | -$231 | – | 3030 |
|
|
2024
Q3 | $231 | Buy |
147
+26
| +21% | +$46 | ﹤0.01% | 2833 |
|
|
2024
Q2 | $203 | Buy |
121
+72
| +147% | +$129 | ﹤0.01% | 2816 |
|
|
2024
Q1 | $118 | Buy |
+49
| New | +$105 | ﹤0.01% | 2702 |
|
|
2023
Q4 | – | Sell |
-184
| Closed | -$201 | – | 2698 |
|
|
2023
Q3 | $201 | Buy |
184
+117
| +175% | +$205 | ﹤0.01% | 2666 |
|
|
2023
Q2 | $153 | Hold |
67
| – | – | ﹤0.01% | 2735 |
|
|
2023
Q1 | $0 | Hold |
67
| – | – | ﹤0.01% | 2616 |
|
|
2022
Q4 | $0 | Buy |
+67
| New | +$143 | ﹤0.01% | 2649 |
|
|
2021
Q2 | – | Sell |
-140,000
| Closed | -$822K | – | 2357 |
|
|
2021
Q1 | $822K | Buy |
140,000
+136,090
| +3,481% | +$942K | 0.01% | 1031 |
|
|
2020
Q4 | $13K | Buy |
3,910
+3,150
| +414% | +$6.01K | ﹤0.01% | 2181 |
|
|
2020
Q3 | $1K | Hold |
760
| – | – | ﹤0.01% | 2243 |
|
|
2020
Q2 | $2K | Hold |
760
| – | – | ﹤0.01% | 2049 |
|
|
2020
Q1 | $1K | Hold |
760
| – | – | ﹤0.01% | 2062 |
|
|
2019
Q4 | $3K | Hold |
760
| – | – | ﹤0.01% | 1973 |
|
|
2019
Q3 | $2K | Hold |
760
| – | – | ﹤0.01% | 1980 |
|
|
2019
Q2 | $5K | Hold |
760
| – | – | ﹤0.01% | 1896 |
|
|
2019
Q1 | $4K | Hold |
760
| – | – | ﹤0.01% | 1939 |
|
|
2018
Q4 | $5K | Hold |
760
| – | – | ﹤0.01% | 1812 |
|
|
2018
Q3 | $8K | Hold |
760
| – | – | ﹤0.01% | 1785 |
|
|
2018
Q2 | $9K | Buy |
760
+120
| +19% | +$1.23K | ﹤0.01% | 1760 |
|
|
2018
Q1 | $5K | Hold |
640
| – | – | ﹤0.01% | 1795 |
|
|
2017
Q4 | $6K | Hold |
640
| – | – | ﹤0.01% | 1804 |
|
|
2017
Q3 | $8K | Hold |
640
| – | – | ﹤0.01% | 1781 |
|
|
2017
Q2 | $11K | Hold |
640
| – | – | ﹤0.01% | 1686 |
|
|
2017
Q1 | $9K | Sell |
640
-560
| -47% | -$8.31K | ﹤0.01% | 1701 |
|
|
2016
Q4 | $17K | Buy |
1,200
+400
| +50% | +$6.42K | ﹤0.01% | 1684 |
|
|
2016
Q3 | $14K | Hold |
800
| – | – | ﹤0.01% | 1743 |
|
|
2016
Q2 | $11K | Buy |
+800
| New | +$10.8K | ﹤0.01% | 1777 |
|
Other funds holding LXRX
AG
SL
SC
Nisa Investment Advisors's LXRX Position: Q2 2026 in Review
Nisa Investment Advisors held its Lexicon Pharmaceuticals (LXRX) position steady in Q2 2026 at 2,592 shares worth $6.22K. The position accounts for ﹤0.01% of the portfolio, ranked #2580.
Nisa Investment Advisors first reported a position in LXRX in Q2 2016 and has held it in 33 quarters since. The position peaked at $822K in Q1 2021. 149 funds tracked by Wall St. Rank hold LXRX as of Q2 2026.
- Nisa Investment Advisors held 2,592 shares of Lexicon Pharmaceuticals worth $6.22K as of Q2 2026.
- Nisa Investment Advisors left its Lexicon Pharmaceuticals share count unchanged in Q2 2026.
- Lexicon Pharmaceuticals made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q2 2026, its #2580 holding.
- Nisa Investment Advisors first reported a position in Lexicon Pharmaceuticals in Q2 2016 and has held it in 33 quarters since.
- Nisa Investment Advisors's Lexicon Pharmaceuticals position peaked at $822K in Q1 2021.
- 149 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2026.
Based on Nisa Investment Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.